Considerable Differences in Vaccine Immunogenicities and Efficacies Related to the Diluent Used for Aluminum Hydroxide Adjuvant-Reference-Cited by-同舟云学术

Considerable Differences in Vaccine Immunogenicities and Efficacies Related to the Diluent Used for Aluminum Hydroxide Adjuvant

Published:2008-03 Issue:3 Volume:15 Page:582-584
ISSN:1556-6811
Container-title:Clinical and Vaccine Immunology
language:en
Short-container-title:Clin Vaccine Immunol

Author:

Lin Lin¹,Ibrahim Ashraf S.¹²,Avanesian Valentina¹,Edwards John E.¹²,Fu Yue¹²,Baquir Beverlie¹,Taub Rebecca¹,Spellberg Brad¹²

Affiliation:

1. Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California

2. the David Geffen School of Medicine at UCLA, Los Angeles, California

Abstract

ABSTRACT We are developing an anticandidal vaccine using the recombinant N terminus of Als3p (rAls3p-N). We report that although more rAls3p-N was bound by aluminum hydroxide diluted in saline than by aluminum hydroxide diluted in phosphate-buffered saline (PBS), its immunogenicity and efficacy were superior in PBS. Thus, protein binding, by itself, may not predict the efficacy of some vaccines with aluminum adjuvants.

Publisher

American Society for Microbiology

Subject

Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy

Link

https://journals.asm.org/doi/pdf/10.1128/CVI.00427-07

Reference19 articles.

1. Baylor, N. W., W. Egan, and P. Richman. 2002. Aluminum salts in vaccines—US perspective. Vaccine20(Suppl. 3):S18-S23.

2. Berthold, I., M. L. Pombo, L. Wagner, and J. L. Arciniega. 2005. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine23:1993-1999.

3. Chang, M., Y. Shi, S. L. Nail, H. HogenEsch, S. B. Adams, J. L. White, and S. L. Hem. 2001. Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine19:2884-2889.

4. Flebbe, L. M., and H. Braley-Mullen. 1986. Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens. Cell. Immunol.99:119-127.

5. Gupta, R. K., E. H. Relyveld, E. B. Lindblad, B. Bizzini, S. Ben-Efraim, and C. K. Gupta. 1993. Adjuvants—a balance between toxicity and adjuvanticity. Vaccine11:293-306.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Road Ahead: Advancing Antifungal Vaccines and Addressing Fungal Infections in the Post-COVID World;ACS Infectious Diseases;2024-09-10

2. Promising immunotherapeutic targets for treating candidiasis;Frontiers in Cellular and Infection Microbiology;2024-02-09

3. Separation of three strains of polio virus by capillary zone electrophoresis and study of their interaction with aluminum oxyhydroxide;Journal of Chromatography A;2022-03

4. The Role of B-Cells and Antibodies against Candida Vaccine Antigens in Invasive Candidiasis;Vaccines;2021-10-10

5. Nanoalum adjuvanted vaccines: small details make a big difference;Seminars in Immunology;2021-08